Vesalius Therapeutics
Pioneering breakthrough treatments for common diseases
- Headquarters
- Cambridge, Massachusetts
- Employees
- 11–50
- Founded
- 2022
- Business Model
- B2B
- Website
- vesaliustx.com
- Total Funding
- $75.0M
- Last Round
- $75.0M Series CMar 2022
About
Founded in 2020 and headquartered in Cambridge, Massachusetts, Vesalius Therapeutics discovers and develops drugs by targeting biological circuits within cells to treat diseases underlying common illnesses such as Parkinson's disease. The company is backed by Flagship Pioneering and has a strategic alliance with GSK to develop novel Parkinson's disease treatments.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account